Generic Drug Reforms: FTC Notification Bill Appears Ready To Move In 2003
This article was originally published in The Tan Sheet
Executive Summary
A bill to require reporting of brand/generic patent settlements to the Federal Trade Commission appears ready to move early in the 108th Congress
You may also be interested in...
FDA Questions First-To-File Exclusivity As Generic Reforms Pass Senate
FDA has reservations about the current first-to-file basis for 180-day exclusivity, FDA Chief Counsel Daniel Troy acknowledged at a June 17 Senate Judiciary Committee hearing on generic drug reforms
FDA Questions First-To-File Exclusivity As Generic Reforms Pass Senate
FDA has reservations about the current first-to-file basis for 180-day exclusivity, FDA Chief Counsel Daniel Troy acknowledged at a June 17 Senate Judiciary Committee hearing on generic drug reforms
FDA Questions First-To-File Exclusivity As Generic Reforms Pass Senate
FDA has reservations about the current first-to-file basis for 180-day exclusivity, FDA Chief Counsel Daniel Troy acknowledged at a June 17 Senate Judiciary Committee hearing on generic drug reforms